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Dbl family members are guanine nucleotide exchange
factors specific for Rho guanosine triphosphatases
(GTPases) and invariably possess tandem Dbl (DH) and
pleckstrin homology (PH) domains. Dbs, a Dbl family
member specific for Cdc42 and RhoA, exhibits trans-
forming activity when overexpressed in NIH 3T3 mouse
fibroblasts. In this study, the PH domain of Dbs was
mutated to impair selectively either guanine nucleotide
exchange or phosphoinositide binding in vitro and re-
sulting physiological alterations were assessed. As an-
ticipated, substitution of residues within the PH domain
of Dbs integral to the interface with GTPases reduced
nucleotide exchange and eliminated the ability of Dbs to
transform NIH 3T3 cells. More interestingly, substitu-
tions within the PH domain that prevent interaction
with phosphoinositides yet do not alter in vitro activa-
tion of GTPases also do not transform NIH 3T3 cell and
fail to activate RhoA in vivo despite proper subcellular
localization. Therefore, the PH domain of Dbs serves
multiple roles in the activation of GTPases and cannot
be viewed as a simple membrane-anchoring device. In
particular, the data suggest that binding of phospho-
inositides to the PH domain within the context of mem-
brane surfaces may direct orientations or conforma-
tions of the linked DH and PH domains to regulate
GTPases activation.
The Rho family GTPases1 are an essential subset of the Ras
superfamily of small molecular weight GTPases. Like Ras, Rho
family GTPases cycle between GDP- and GTP-bound forms.
When GDP-bound, Rho proteins are inactive and do not func-
tionally couple to their downstream effectors. However, when
GTP-bound, Rho GTPases elicit profound effects on the orga-
nization of the actin cytoskeleton, in addition to tightly regu-
lating the activation state of transcription factors such as the
serum response factor, c-Jun, and NF-B (1–3). GDP/GTP cy-
cling within Rho proteins is primarily accomplished through
the actions of two classes of regulatory proteins. GTPase acti-
vating proteins promote the inactive, GDP-bound form of Rho
proteins by enhancing their intrinsic GTPase ability to convert
bound GTP to GDP. In contrast, the actions of guanine nucle-
otide exchange factors (GEFs) upon Rho GTPases results in
Rho activation by exchanging their bound GDP for GTP.
Members of the Dbl family of oncoproteins act as GEFs
exclusively for Rho GTPases (RhoGEFs) and, like constitu-
tively activated members of Rho GTPases, can exhibit potent
transformation potential within various cell types upon over-
expression or constitutive activation (4–6). Dbl family mem-
bers invariably contain a Dbl homology (DH) domain in tandem
with an adjacent, carboxyl-terminal pleckstrin homology (PH)
domain. However, outside of this region, Dbl-related proteins
share little sequence conservation and typically possess a va-
riety of protein-signaling domains, presumably reflecting di-
versity in regulation and cellular function.
The invariant positioning of PH domains immediately car-
boxyl-terminal to DH domains strongly implies a unique func-
tional coupling. As demonstrated by several complementary
studies, DH-associated PH domains are essential components
of Dbl family activation of Rho family GTPases. Truncation of
all or part of the PH domains of Dbl (7), Dbs (8), Lfc (9), and Lsc
(10) results in the complete loss of cellular transformation.
Replacing the PH domains of Lfc and Dbs with a membrane-
targeting sequence restores at least partial transforming activ-
ity, indicating a role in membrane targeting for these PH
domains, presumably through interaction with phosphoinositi-
des, i.e. low affinity (micromolar KD), nonspecific ligands for the
vast majority of PH domains (11). In addition to possibly me-
diating the translocation of Dbl family proteins to cellular
membranes, phosphoinositides may also potentiate or suppress
the exchange activity of some Dbl family proteins in solution
(12–14); however, this does not appear to be a general mecha-
nism of regulation (15). Moreover, recent evidence indicates
that PH domains associated with DH domains can accelerate
the catalytic exchange of nucleotides on Rho family GTPases
independent of phosphoinositides. For example, a DH/PH frag-
ment of Trio catalyzes nucleotide exchange within Rac 200-
fold better than the isolated DH domain (16).
The PH domain of Dbs makes direct contacts to Cdc42, and
these interactions are necessary for efficient guanine nucleo-
tide exchange in vitro (17). In this study, we define functional
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roles for the PH domain of Dbs in directly mediating cellular
transformation associated with downstream signaling events,
especially the in vivo activation of GTPases. We found that
mutations within the PH domain of Dbs, previously shown to
be necessary for exchange in vitro, completely eliminated the
ability of Dbs to transform NIH 3T3 cells. More interestingly,
mutations within the PH domain that prevent binding of phos-
phoinositides, but not in vitro nucleotide exchange by Dbs, also
prevent Dbs from activating RhoA in vivo and do not allow the
transformation of NIH 3T3 cells by a normally highly oncogenic
form of Dbs. These effects were not caused by the mislocaliza-
tion of Dbs, because none of the mutations affected subcellular
targeting as assessed by cellular fractionations and indirect
immunofluorescence. Therefore, the PH domain of Dbs must be
functioning in some capacity other than a simple membrane
anchor dependent upon binding phosphoinositides to alter the
gross subcellular distribution of Dbs leading to GTPase activa-
tion. Indeed, the data are more consistent with phosphoinosi-
tide binding being required to direct orientation or conforma-
tions of the invariantly associated DH and PH domains with
respect to cellular membranes and membrane-resident
GTPases for regulated guanine nucleotide exchange.
EXPERIMENTAL PROCEDURES
Molecular Constructs—pAX142-dbs-HA6 and pCTV3H-dbs-HA6 con-
tain cDNAs that encode fragments of murine Dbs fused to an HA
epitope tag and include the Dbs DH/PH domain along with amino- and
carboxyl-terminal flanking regions (residues 525–1097) (18). pCTV3H-
dbs-HA8 encodes an HA epitope-tagged Dbs DH domain (residues 525–
833), whereas pCTV3P-dbs-HA7 encodes the Dbs DH domain fused to
the plasma membrane-targeting sequence (GCMSCKCVLS) of H-Ras
(Dbs DH plus CAAX).
GST-C21 contains the RhoGTP binding domain of Rhotekin (19).
pEGFP (Clontech) used for immunofluorescence studies contains GFP
under the control of a cytomegalovirus promoter.
The Dbs DH/PH domain (murine, residues 623–967), fused to a
carboxyl-terminal hexa-histidine tag, was expressed in Escherichia coli
from pET-28a (Novagen) (17). A pET-21a (Novagen) expression con-
struct was used to bacterially express human placental Cdc42 (residues
1–188, C188S) (17). Human RhoA (residues 1–190, C190S), fused to an
amino-terminal hexa-histidine tag, was expressed from pProEX-HT
(Invitrogen). The PH domain of PLC-1 (residues 11–140), fused to an
amino-terminal hexa-histidine tag, was also expressed from the
pProEX-HT vector for bacterial expression. Site-directed substitutions
placed within all Dbs DH/PH domains and Cdc42 expression constructs
were prepared using the QuikChange site-directed mutagenesis kit
(Stratagene) as per the manufacturer’s instructions and were verified
by automated sequencing.
Protein Expression and Purification—Protein expression in stably
transfected NIH 3T3 cells was determined by Western blot analysis as
described previously (9). Protein was visualized with Enhanced Chemi-
luminescence reagents (Amersham Biosciences). Protein expression
and purification of Dbs DH/PH domains, Cdc42(C188S) and
RhoA(C190S) from E. coli, were performed as described previously
(17, 20).
Guanine Nucleotide Exchange Assays—Fluorescence spectroscopic
analysis of N-methylanthraniloyl (mant)-GTP incorporation into bacte-
rially purified Cdc42 and RhoA was carried out using a PerkinElmer
Life Sciences LS 50B spectrometer at 25 °C. Exchange reaction assay
mixtures, containing 20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1
mM dithiothreitol, and 100 M mant-GTP (BIOMOL), and either 1 or 2
M (as indicated) of either Cdc42 or RhoA protein, were prepared and
allowed to equilibrate with continuous stirring. After equilibration, Dbs
DH/PH domain proteins were added at 200 nM, and the rates of nucle-
otide loading (kobs) of Rho GTPases were determined by monitoring the
decrease in Cdc42 or RhoA tryptophan fluorescence (ex  295 nm,
em  335 nm) in response to binding mant-GTP. The rates (kobs) of
guanine nucleotide exchange were determined by fitting the data as
single-exponential decays utilizing the program GraphPad Prism. Data
were normalized to wild-type curves to yield the percent GDP released.
Cell Culture, Transfection, and Transformation Assays—NIH 3T3
cells were maintained in Dulbecco’s modified Eagle medium (high glu-
cose) supplemented with 10% bovine calf serum (NIH 3T3, JRH,
Lenexa, KS). Primary focus formation assays were performed in NIH
3T3 cells exactly as described previously (21). Briefly, NIH 3T3 cells
were transfected by calcium phosphate coprecipitation in conjunction
with a glycerol shock. Focus formation was scored at 14 days. NIH 3T3
cells that stably express pCTV3H, pCTV3H-dbs-HA6, or the pCTV3H
versions of Dbs mutants were generated by calcium phosphate copre-
cipitation followed by selection for 14 days in growth medium supple-
mented with hygromycin B (200 g/ml). Multiple drug-resistant colo-
nies (100) were pooled together to establish stable cell lines. All assays
for transformation were performed in triplicate.
Docking of Ins(4,5)P2 onto the PH Domain of Dbs—Potential lipid
binding pockets on the surface of the Dbs PH domain were predicted
using the SiteID option of SYBYL (Tripos Inc.). A coordinate file for
the phosphoinositol ring of phosphatidylinositol 4,5-bisphosphate
(Ins(4,5)P2) was created using SYBYL. All docking procedures utilized
the DOCK suite of programs (version 4.0, I. D Kuntz, University of
California at San Francisco) and were carried out in a manner previ-
ously reported (22). Briefly, a molecular surface for each potential
binding pocket was generated using the surface calculation algorithm
MS (23) and used as an input for generating space-filling spheres using
Sphgen. A scoring grid encompassing each pocket plus an additional
radius of 8 Å was calculated using the grid. Parameters used for
docking Ins(4,5)P2 into the Dbs PH domain were standard DOCK pa-
rameters for the single anchor search method using torsion drive and
torsion minimization. Residues 846–852 in the disordered 1/2 loop
region were modeled in and minimized for some docking procedures. To
validate our docking procedure, inositol 1,4,5-trisphosphate was suc-
cessfully docked into the previously determined structure of the PH
domain of PLC- bound to inositol 1,4,5-trisphosphate (RCSB accession
number 1MAI).
Phosphoinositide Binding Assays—The ability of His6-tagged Dbs
proteins to bind to phosphatidylinositol 4,5-bisphosphate was assessed
by an enzyme linked immunosorbent assay (ELISA) utilizing a 96-well
microtiter plate containing a various amounts of diC6-modified phos-
phatidylinositol 4,5-bisphosphate (Echelon Biosciences Inc.). Protein
stock solutions were diluted to 10 M in buffer C (20 mM Tris, pH 7.5,
100 mM NaCl, and 5% glycerol) before adding 50 l of each protein to
the wells. 100 l of an anti-His antibody (Santa Cruz Biotechnology)
diluted 1:500 in buffer C was then incubated with each well, followed by
100 l of an horseradish peroxidase-conjugated sheep anti-mouse IgG
(Amersham Biosciences) diluted 1:1000 in buffer C. All incubations
were performed for 1 h at 18 °C, and the wells were extensively washed
with buffer C after each incubation step. Protein-lipid interactions were
detected with the horseradish peroxidase substrate o-phenylenedia-
mine (Sigma), and absorbances were measured at 490 nm.
Dbs binding to small unilamellar vesicles (SUVs) containing phos-
phatidylinositol 4,5-bisphosphate was measured by surface plasmon
resonance using a BIAcore 2000 instrument. SUVs (containing by mo-
lar fraction 80% dipalmitoyl phosphatidylcholine, 17% dipalmitoyl
phosphatidylserine, 3% phosphatidylinositol 4,5-bisphosphate, and
0.1% N-biotinylated dipalmitoyl phosphatidylethanolamine) were pre-
pared by sonicating lipids into 20 mM Hepes (pH 7.5) and 150 mM NaCl.
SUVs were then captured on an SA5 chip (BIAcore) via a biotin-strepta-
vidin interaction. Equal amounts of SUVs were immobilized on each
respective flow cell, whereas an empty flow cell was maintained to
control for nonspecific binding. 25 l of various Dbs proteins in 20 mM
Hepes (pH 7.5) and 150 mM NaCl were injected onto the flow cells at 50
M and followed by 100 l of buffer. Experiments were performed at
25 °C with a flow rate of 100 l/min. Raw sensorgrams from each
experiment were aligned, and the signal due to binding the empty flow
cell was subtracted from each curve using the software BIAevaluation
3.0 (24).
RhoA Activation Assays—The Rho binding domain of Rhotekin (GST-
C21) (19) was expressed as a GST fusion in BL21(DE3) cells and
immobilized by binding to glutathione-coupled Sepharose 4B beads
(Amersham Biosciences). The immobilized GST-C21 was then used to
precipitate GTP-bound RhoA from NIH 3T3 cell lysates. Cells were
washed in cold phosphate-buffered saline and then lysed in 50 mM
Tris-HCl, pH 7.4, 2 mM MgCl2, 100 mM NaCl, 10% glycerol, 1% Nonidet
P-40, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 g/ml aprotinin, and 1
g/ml phenylmethylsulfonyl fluoride. Cell lysates were then cleared by
centrifugation at 10,000  g for 5 min at 4 °C. Lysates used for affinity
purification were normalized for endogenous Rho levels. Affinity puri-
fications were carried out at 4 °C for 1 h, washed three times in an
excess of lysis buffer, and then analyzed by Western blot. RhoA was
detected by a monoclonal antibody (sc-418, Santa Cruz Biotechnology).
Immunofluorescence—NIH 3T3 cells were plated on coverslips and
then transiently cotransfected with 1 g of pEGFP (Clontech) and 3 g
of either pAX142 or pAX142-dbs-HA6 harboring the PH domains mu-
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tations by calcium phosphate precipitation. Cells were fixed with 3.7%
formaldehyde (in PBS) for 10 min, permeabilized, and blocked in 0.1%
Triton X-100, 3% BSA in PBS for 30 min. Coverslips were then incu-
bated in a humidity chamber with an anti-HA mouse monoclonal anti-
body (BAbCO) for 1 h in 0.1% Triton X-100 with 0.1% BSA, washed in
PBS, and then incubated with red-fluorescent Alexa Fluor 488-conju-
gated goat anti-mouse IgG (0.1% Triton X-100, 0.1% BSA, Molecular
Probes) for 30 min in the dark. Coverslips were washed in PBS and
mounted on glass slides using FluorSave reagent (Calbiochem). Cells
were viewed with an Olympus IX50 inverted confocal microscope, and
images were captured using the optronics digital charge-coupled device
camera system.
Membrane Fractionation Analyses—Mass populations of NIH 3T3
cells stably expressing Dbs-HA6 or Dbs-HA6 harboring a PH domain
mutation were washed with ice-cold PBS and resuspended in cold
HYPO buffer (10 mM Tris, pH 7.4, 1 mM MgCl2, 5 g/ml leupeptin, 5
g/ml aprotinin, 5 g/ml pepstatin, 1 mM phenylmethylsulfonyl fluo-
ride). Lysates were then homogenized, harvested with HYPO buffer
supplemented with 0.15 M NaCl, and then centrifuged at 38,000 rpm for
30 min at 4 °C. The supernatant (cytosolic fraction) was removed, and
the pellet (particulate fraction) was resuspended in HYPO buffer sup-
plemented with 0.15 M NaCl. The protein concentrations of the total,
cytosolic, and membrane fractions were determined with a bicincho-
ninic acid protein assay kit (Pierce). 30 g of protein for each fraction
was resolved by SDS-PAGE, transferred to Immobilon-P membranes
(Millipore), and probed with anti-HA epitope antibody (BAbCO).
RESULTS
The PH Domain of Dbs Is Integral to the Interface with Rho
GTPases Necessary for Guanine Nucleotide Exchange and Cel-
lular Transformation—The recently reported structure of a
fragment of Dbs in complex with Cdc42 highlights a crucial role
for the PH domain in promoting an extensive set of interactions
between Dbs and Cdc42 necessary for efficient guanine nucle-
otide exchange in vitro (Fig. 1A) (17). In particular, Tyr-889
within 4 of the PH domain is critical for exchange because its
substitution to phenylalanine dramatically decreases Dbs-cat-
alyzed exchange of both Cdc42 and RhoA without affecting the
overall arrangement of domains within the DbsCdc42 complex
(17). To clarify the structural role of the PH domain in contrib-
uting productively to the interface between Dbs and GTPases,
a series of substitutions within the interface were assessed for
functional importance. In particular, Arg-66 of Cdc42 interacts
with multiple residues within the PH domain of Dbs, including
Tyr-889. Yet substitution of Arg-66 to alanine does not affect
nucleotide exchange (Fig. 1B, Table I, and see Ref. 17), sug-
gesting that Tyr-889 likely stabilizes the electronic configura-
tion of His-814 to promote interaction with Asp-65 of Cdc42. In
support of the importance of Asp-65 to nucleotide exchange,
amino acid substitutions placed at Asp-65 (D65A, D65E, and
D65N) severely limit the ability of Dbs to activate Cdc42 (Fig.
1B and Table I). Of particular note, the isosteric substitution
D65N in Cdc42 should not disrupt interactions with Asn-810 of
the DH domain but will disrupt hydrogen bonding with His-814
of Dbs. Consistent with an “uncoupling” of Asp-65 from Tyr-
889, Cdc42 (D65N) suffers a reduction of 7-fold in the activa-
tion by Dbs, on par with the effect of Dbs(Y889F) on wild-type
Cdc42 (Table I).
The in vitro exchange assays utilizing mutants of Dbs and
Cdc42 strongly suggest that the PH domain of Dbs, acting in
concert with the DH domain, is necessary to fully activate Rho
family GTPases within cells. To further assess the physiologi-
cal function of the PH domain of Dbs in activating Rho
GTPases, we introduced a subset of the previously studied
mutations into a transforming version of Dbs (Dbs-HA6) (8)
and measured the capacities of the mutated proteins to trans-
form NIH 3T3 cells (Fig. 1C). Dramatically, whereas Dbs-HA6
possesses potent transformation activity, either H814A or
Y889F completely eliminates the focus-forming activity of Dbs-
HA6 in NIH 3T3 cells. Similarly, K885A, which is also within
the PH domain, significantly reduces transformation by Dbs.
Because transformation of Dbs depends upon activation of
RhoA in NIH 3T3 cells (25), these data suggest that the PH
domain of Dbs is required for direct activation of Rho family
proteins, irrespective of membrane targeting. These effects are
not due to loss of affinity for phosphoinositides by Dbs, because
Dbs(H814A), Dbs(Y889F), and Dbs(K885A) bind to phosphati-
dylinositol 4,5-bisphosphate similar to wild-type Dbs (Fig. 2, B
and C).
Mapping the Interface within the PH Domain Necessary for
Binding Phosphoinositides—Typically, the majority of pleck-
strin homology domains bind phosphoinositide headgroups
with low affinity and specificity. For instance, the PH domain
of Dbs promiscuously binds several multiphosphorylated phos-
phoinositides with low affinity, including phosphatidylinositol
3,4-bisphosphate and phosphatidylinositol 4,5-bisphosphate
(15). Primary sequence analysis and structural homology com-
parisons suggest Dbs binds phosphoinositides similarly to
FIG. 1. Interactions between the PH domain of Dbs and Rho
GTPases are critical for transformation. A, as previously reported
(17), the PH domain (blue, disorder region in gray) of Dbs is an integral
part of the interface with Cdc42 (green, switch regions are red) and the
DH domain (yellow) necessary for robust GEF activity in vitro. The inset
highlights specific interactions with dashed lines indicating potential
hydrogen bonds. B, within Cdc42, Asp-65, but not Arg-66, is critical for
exchange supported by the PH domain. Asp-65 of Cdc42 interacts
primarily with His-814 of the DH domain buttressed by Gln-834 and
Tyr-889 of the PH domain. Guanine nucleotide exchange reactions were
performed by stimulating 2 M of wild-type or mutant Cdc42 by 0.2 M
of the Dbs DH/PH domain. The intrinsic exchange data for the D65N,
D65E, and D65A Cdc42 mutants are not shown. C, residues within the
PH domain and integral to the interface with Cdc42 are necessary for
transformation of NIH 3T3 cells mediated by Dbs (3 g of plasmid).
Data shown are representative of three assays performed on triplicate
plates. The error bars indicate standard deviations.
TABLE I
Rate constants of Dbs catalyzed guanine nucleotide exchange of
mutant Cdc42 proteins
The rates (kobs) for GEF reactions were determined by fitting the data
from Fig. 1B as single exponential decays. The -fold stimulation for each
Dbs protein reflects the ratio of the kobs measured for the GEF-contain-
ing reaction to the unstimulated reaction containing no GEF.
2 M Cdc42 Intrinsic rate Plus 0.2 M Dbs Stimulation
kobs s
1  103 -fold
Wild type 0.24  0.01 14.89  0.02 61
D65A 0.40  0.00 1.05  0.08 3
D65E 0.19  0.00 2.34  0.00 12
D65N 0.28  0.03 2.60  0.14 9
R66A 0.34  0.02 19.56  0.26 57
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other PH domains largely through residues in and surrounding
the 1/2 and 3/4 loops of the PH domain. Like most PH
domains, the 1/2 and 3/4 loop region of Dbs exhibits a
large envelope of positive electrostatic potential, compatible
with binding the electronegative headgroups of phosphoinositi-
des (17). To further define the lipid-binding pocket within the
Dbs PH domain, we used a computational approach to dock
various inositol phosphates onto the surface of the protein (Fig.
2A). These analyses suggest that residues within the PH do-
main of Dbs that are predicted to contact phosphoinositides
within this site, and/or contribute to the positive electrostatic
potential include: Lys-849, Lys-851, Arg-855, and Lys-857
(within the 1/2 loop); Arg-861 (at the base of 2); Lys-874
(within 3); and Lys-892 (within 4).
To determine if regions comprising 1/2 and 3/4 of the
PH domain of Dbs are responsible for mediating binding to
phosphoinositides, we substituted the identified lysine and ar-
ginine residues with glutamate and assessed the effect of each
mutation upon the ability of Dbs to bind phosphatidylinositol
4,5-bisphosphate. Initially, an enzyme-liked immunosorbent
assay (ELISA) was used to assess binding to phosphatidylinosi-
tol 4,5-bisphosphate in the absence of secondary lipids (Fig.
2B). These results were supported by a more detailed analysis
using surface plasmon resonance and small unilamellar vesi-
cles containing a low molar fraction of phosphatidylinositol
4,5-bisphosphate within a background of negatively charged
lipids (Fig. 2C). As we observed previously (15), wild-type Dbs
DH/PH domain binds significantly to phosphatidylinositol 4,5-
bisphosphate, whereas the isolated DH domain of Dbs shows no
binding. In comparison, Dbs proteins harboring either single or
double glutamate substitutions within the putative phospho-
inositide binding site of the PH domain do not significantly
bind phosphatidylinositol 4,5-bisphosphate in either assay. In
contrast, other mutations within the extended 3/4 loop
(K885A) or 4 loop (Y889F) of the PH domain, at sites distinct
from the phosphoinositide-binding pocket, do not significantly
affect binding of phosphoinositides. Therefore, as observed
within the structures of other PH domains bound to inositol
phosphates, the PH domain of Dbs binds lipids through por-
tions of 1/2 and 3/4, and mutations within this pocket
selectively abolish lipid binding.
RhoA Activation and Cellular Transformation Require En-
gagement of Phosphoinositides by the PH Domain—To assess if
phosphoinositide binding to the PH domain is critical for Dbs
transformation of NIH 3T3 cells, we placed each mutation into
the Dbs-HA6 construct and compared transformation poten-
tials in primary focus formation assays (Fig. 3A). Strikingly,
except for the low level of foci formation exhibited by
Dbs(K874E), transformation was completely eliminated by all
other mutations within the pocket of the PH domain responsi-
FIG. 2. Mutational analysis of the phosphoinositide-binding
pocket. A, model of the headgroup of phosphatidylinositol 4,5-bisphos-
phate docked onto the PH domain of Dbs. The inositol ring of phosphati-
dylinositol 4,5-bisphosphate was docked onto the crystal structure of
the PH domain of Dbs (PDB code 1KZ7) using the program DOCK (22).
The electropositive surface (blue) was used during docking, and the
top-scoring complex is shown with residues that impair binding of
phosphoinositides upon mutation labeled. B, all substitutions within
the putative phosphoinositide-binding pocket of Dbs DH/PH abrogate
binding of phosphatidylinositol 4,5-bisphosphate as measured by mi-
crotiter-based ELISA. Conversely, mutations within the DH domain
(H814A) or the 3/4 loop of the PH domain have insignificant effects
on phosphatidylinositol 4,5-bisphosphate binding. Also shown is the
binding profile for the PH domain of PLC-1 known to bind phosphati-
dylinositol 4,5-bisphosphate with high affinity (40) as well as the iso-
lated DH domain of Dbs. C, similar binding results were obtained using
small unilamellar vesicles doped with phosphatidylinositol 4,5-bisphos-
phate at 3% mol fraction and measuring interactions by surface plas-
mon resonance. Raw data were normalized to the signal achieved from
nonspecific binding to an empty flow cell surface.
FIG. 3. In vivo activation of RhoA and associated transforma-
tion require phosphoinositide binding to the PH domain. A,
mutations within the PH domain of Dbs that destroy binding to phos-
phoinositides also prevent transformation of NIH 3T3 cells as measured
in primary focus formation assays. Data shown are representative of
three independent assays performed on triplicate plates. B, the identi-
cal panel of mutants also fails to activate RhoA in NIH 3T3 cells.
Lysates were prepared from cell lines stably expressing either Dbs-
HA6, the various mutations within a Dbs-HA6 background, or the
cognate pCTV3H vector and examined by Western blot for expression of
RhoA (Total-RhoA) and the HA-tagged Dbs proteins (anti-HA). Each
lysate was subsequently normalized for expression of total RhoA and
subjected to affinity purification using immobilized GST-C21 to isolate
RhoA-GTP also visualized by Western blot. All experiments were per-
formed a minimum of three times, and data shown constitute a repre-
sentative set.
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ble for binding phosphoinositides. Although exact identification
of the endogenous phosphoinositide targeted by Dbs awaits
more detailed analyses, these data resoundingly highlight that
phosphoinositide binding by the PH domain is essential for
Dbs-mediated transformation.
Dbs transformation of NIH 3T3 cells is closely correlated to
the activation of endogenous pools of RhoA and not Cdc42 (25).
Because the mutations within the PH domain destroy trans-
forming activity in primary focus assays, an associated de-
crease in the levels of activated RhoA in these cells is expected.
To measure endogenous levels of activated RhoA, the Rho-
binding domain of Rhotekin was used to precipitate GTP-bound
RhoA from lysates of NIH 3T3 cells expressing either wild-type
Dbs-HA6 or Dbs-HA6 harboring the previously characterized
mutations within the PH domain (Fig. 3B). Although Dbs-HA6
exhibited robust activation of RhoA, activation of RhoA was not
detectable in cells expressing the mutant versions of Dbs that
were previously shown to be defective in binding phosphati-
dylinositol 4,5-bisphosphate and transformation. The loss of
transformation and RhoA activation was not a result of poor
expression or stability of the various Dbs mutants, because the
expression levels for all Dbs proteins were found to be equiva-
lent (Fig. 3B, lower panel). These data demonstrate that cellu-
lar transformation of NIH 3T3 cells is dependent upon RhoA
activation and both processes require Dbs to functionally en-
gage phosphoinositides.
However, the formal possibility exists that the observed loss
of in vivo transforming activity and RhoA activation results
from reduction of the inherent GEF activity of Dbs and not the
loss of phosphoinositide binding upon introducing substitutions
within the Dbs PH domain. To determine the functional con-
sequences of substitutions within the lipid binding site of Dbs
upon guanine nucleotide exchange, we analyzed the ability of
each mutant to exchange Cdc42 and RhoA in vitro (Fig. 4 and
Table II). As expected, none of the mutations within the PH
domain of Dbs were detrimental to Dbs-stimulated exchange of
Cdc42 or RhoA, and both the K874E and K892E mutations
within Dbs actually resulted in a modest, but reproducible,
increase in exchange activity of the GEF (Fig. 4, B and D, and
Table II). In summary, removing the ability of Dbs to interact
with phosphoinositides results in the complete loss of both
transforming ability as well as the ability of Dbs to activate
endogenous pools of RhoA.
Proper Subcellular Localization of Dbs Does Not Require the
PH Domain to Bind Phosphoinositides—It is widely assumed
that PH domains generally promote association of their host
proteins to membranes dependent upon specific phospho-
inositides. However, only high affinity interactions of PH do-
mains with phosphoinositides are capable of inducing efficient
membrane localization (11), and the relatively low affinity be-
tween the PH domain of Dbs and phosphatidylinositol 4,5-
bisphosphate (15) argues against a critical role for phospho-
inositides in localizing Dbs to cellular membranes. To assess
potential linkage between the binding of phosphoinositides to
the PH domain and the subcellular localization of Dbs, the
previously characterized mutations within the PH domain
shown to abrogate binding of phosphoinositides were assessed
for affects on the cellular distribution of Dbs determined by
membrane fractionation (Fig. 5A). Contrary to the straightfor-
ward idea of the PH domain as a simple membrane-tethering
device, none of the mutations within the PH domain grossly
altered the subcellular distribution of an extended fragment of
Dbs (Dbs-HA6) stably expressed in NIH 3T3 cells and contain-
ing both DH and PH domains as well as flanking sequences.
The lack of observable changes in membrane localization of the
Dbs mutants were not due to the insensitivity of our assay,
because a membrane-targeted version of the Dbs DH domain
(DH-CAAX) was nearly entirely associated with the insoluble,
membrane fraction. In contrast, a non-targeted DH domain is
distributed largely within the cytoplasm of NIH 3T3 cells as
previously reported (18). These data demonstrate that, al-
though the PH domain and surrounding regions are necessary
for the recruitment of Dbs to cellular membranes, this recruit-
ment is independent of the need for the PH domain to bind
phosphoinositides.
Results arising from the cellular fractionations are sup-
ported by more detailed immunofluorescence studies (Fig.
5B). When transiently expressed in NIH 3T3 cells, Dbs-HA6
localizes predominantly in membrane structures that coin-
cide with lamellipodia and dense cytoplasmic pockets of in-
determinate identity. Importantly, the entire panel of muta-
tions within the PH domain previously tested by cellular
fractionations similarly have no effect on subcellular local-
ization; Dbs-HA6(K892E) is shown as a representative exam-
ple. Similarly, stable expression of the panel of mutant pro-
teins shows no alterations in subcellular distribution relative
to wild-type Dbs, although staining is weaker and more dif-
fuse (data not shown). Fragments of Dbs, truncated before
the PH domain (wild-type Dbs DH, Fig. 5A) as well as the
isolated PH domain,2 are predominantly cytosolic; therefore,
regions carboxyl-terminal of the PH domain are likely to
direct subcellular localization of Dbs. Future studies will test
this idea. Given that the entire panel of mutants is defective
in binding phosphoinositides through the PH domain yet
retains wild-type ability to localize within cells as determined
by both subcellular fractionation and immunofluorescence, it
seems unequivocal that localization of Dbs to cellular com-
partments is independent of any requirement of the PH do-
main to bind phosphoinositides.
DISCUSSION
The invariant positioning of PH domains immediately car-
boxyl-terminal to DH domains strongly implies a unique func-
tional interrelationship. Recent structures of several DH/PH
fragments bound to Rho GTPases highlight a highly conserved
2 K. L. Rossman, L. Cheng, G. M. Mahon, R. J. Rojas, J. T. Snyder,
I. P. Whitehead, and J. Sondek, unpublished data.
FIG. 4. In vitro GEF activity of Dbs is unaffected by loss of
phosphoinositide binding to the PH domain. In vitro guanine
nucleotide exchange of Cdc42 (A and B) or RhoA (C and D) by each
phosphoinositide binding site mutant of Dbs was carried out as de-
scribed under “Experimental Procedures.” Guanine nucleotide ex-
change reactions were performed by stimulating 1 M of GTPase by 0.2
M of wild-type or mutant Dbs DH/PH domain. “None” refers to the
intrinsic exchange data of wild-type Cdc42 or RhoA in the absence of
GEF.
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mechanism of exchange by DH domains (15, 17, 26). However,
there is mounting evidence that PH domains associated with
DH domains can cooperate in the exchange process. For exam-
ple, relative to the isolated DH domain, the DH/PH fragment of
Trio is more efficient at catalyzing nucleotide exchange upon
Rac1 in vitro (16). Similarly, DH/PH fragments of p115 Rho-
GEF, Dbl, and Dbs are more proficient GEFs relative to their
isolated DH domains (17, 27, 28).
Importantly for Dbs, the underlying mechanism for the PH
domain-associated increase in the rate of nucleotide exchange
has been revealed within the structure of DbsCdc42. The
structure shows that the PH domain of Dbs interacts with
Cdc42 through interactions within 1, 4, and the 3/4 loop of
the PH domain to contact switch 2 and 3b within Cdc42, and
biochemical studies show these interactions are critical for
efficient guanine nucleotide exchange in vitro (17). In particu-
lar, mutation of Tyr-889 to phenylalanine within the Dbs PH
domain was particularly detrimental to guanine nucleotide
exchange. Here we show that Tyr-889 likely acts to encourage
interactions between Asp-65 within Cdc42 (Asp-67 in RhoA)
and His-814 within the Dbs DH domain. Consistent with the
related in vitro results, Dbs harboring Y889F (or H814A) failed
to transform NIH 3T3 cells. These effects are not due to an
inability to bind phosphoinositides, because Dbs(Y889F) pos-
sesses wild-type affinity toward phosphoinositides (Fig. 2) and
maintains a three-dimensional structure essentially identical
to wild-type Dbs (17). Therefore, both the DH and PH domains
of Dbs are critical for directly catalyzing the activation of Rho
GTPases in cells.
Pleckstrin homology domains typically associate with phos-
phoinositides, and the lipid binding sites are predominantly
composed of residues in and around the 1/2 and 3/4 loops
(11, 29). Based on docking experiments between inositol 4,5-
bisphosphate (the phosphoinositol ring of phosphatidylinositol
4,5-bisphosphate) and the Dbs PH domain, basic residues
within the Dbs PH domain that participate in phosphatidyl-
inositide binding have been predicted. Consistent with these
predictions, substitutions to glutamate at these sites abolish
the ability of Dbs to productively bind to phosphatidylinositol
4,5-bisphosphate in vitro. When the mutants of Dbs that are
deficient in binding lipid are analyzed for in vivo function, they
are completely devoid of transformation potential and do not
TABLE II
Rate constants of guanine nucleotide exchange reactions catalyzed by wild-type and mutant Dbs proteins on Cdc42 and RhoA
kobs values and -fold stimulation were estimated as in Table I using data from Fig. 4.
Dbs
Cdc42 RhoA
kobs Stimulation kobs Stimulation
s1  103 -fold s1  103 -fold
None 0.28  0.00 1 0.12  0.00 1
DH/PH (wt) 17.39  0.98 63 4.22  0.35 35
K849E/K851E 15.16  0.31 55 4.17  0.11 34
K855E/K857E 16.09  0.23 58 4.41  0.14 36
R861E 16.90  0.78 61 4.00  0.09 33
K874E 20.48  1.30 74 6.35  0.07 52
K892E 23.37  0.90 84 6.35  0.14 52
K874E/K892E 23.57  1.12 85 7.09  0.09 58
FIG. 5. Mutations within the PH domain of Dbs that destroy
lipid binding do not affect subcellular localization. A, NIH 3T3
cells that stably express Dbs-HA6, Dbs-HA8 (DH), Dbs-HA7 (DH plus
CAAX), or the various lipid binding mutants were lysed and fraction-
ated as described under “Experimental Procedures.” 30 g of protein
from total (T), soluble (S), and particulate (P) fractions were resolved by
SDS-PAGE. Protein expression was determined with an anti-HA
epitope antibody (BAbCO). Data shown are representative of three
independent assays. B, NIH 3T3 cells, which were transiently cotrans-
fected with pEGFP and either Dbs-HA6 or Dbs-HA6 harboring mutants
defective in lipid binding, were examined for cellular distribution of
Dbs. GFP was used as both a counterstain and a marker for transfected
cells. Cells expressing only GFP were examined for expression of the
HA epitope. GFP and HA images were merged (merge) to orient the Dbs
staining with respect to cellular structures.
FIG. 6. Model linking the binding of phosphoinositides to ac-
tivation of Rho GTPases. Prior to GTPase activation (left panel), local
accumulation of specific phosphoinositides and membrane-resident, in-
active GTPases favor interactions with GEFs located in close approxi-
mation to the relevant cellular membranes. For wild-type GEFs (upper
panel), interactions with phosphoinositides and GTPases promote ejec-
tion of GDP and the subsequent loading of GTP to activate GTPases.
For Dbs, exchange requires the direct interactions of both the DH and
PH domains with Rho GTPases at the membrane surfaces to allow both
domains to participate effectively in GTPase activation. Mutations
(lower panel) that destroy the ability of the Dbs PH domain to bind
either phosphoinositide (dimple in the PH domain) or GTPase (bump)
consequently destroy GTPase activation without altering the sub-cel-
lular localization of Dbs. Most significantly, this model invokes the PH
domain in directly regulating GTPase activation by detecting both
GTPases and phosphoinositides, making the PH domain an active par-
ticipant in the exchange process and not simply a membrane-anchoring
device.
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detectably activate RhoA in NIH 3T3 cells, despite suffering no
loss in exchange activity in vitro. Therefore, lipid binding by
the PH domain of Dbs is critical to both the transformation
potential of Dbs and the ability of Dbs to activate Rho GTPases
in vivo.
The binding of phosphoinositides to PH domains is often
invoked to explain the translocation of cytosolic proteins to
membrane surfaces. However, for Dbs, this function does not
appear to be the main role for the PH domain. For instance,
the PH domain of Dbs binds phosphatidylinositol 4,5-
bisphosphate with relatively low affinity (KD of 10 M) (15)
typically considered insufficient to recruit proteins to plasma
membranes (11). Therefore, not surprisingly, mutants of Dbs
deficient in binding phosphoinositides through the PH do-
main continue to associate with distinct cellular compart-
ments similar to wild-type Dbs as assessed by membrane
fractionation and immunofluorescence studies. Other Dbl
family proteins behave similarly. For example, the affinity of
phosphatidylinositol 4,5-bisphosphate binding to the PH do-
main of Sos1 is 2 M (30, 31) and while the PH domain of
Sos1 translocates to plasma membranes in response to se-
rum-treatment of cells, this recruitment is not due to associ-
ation with phosphoinositides but likely involves association
with other ligands (31). In fact, whenever it has been meas-
ured (12, 15, 32, 33) affinities between DH-associated PH
domains and phosphoinositides are sufficiently low as to
suggest a role other than membrane targeting as the princi-
pal function for these PH domains.
An alternative model consistent with the available data
postulates that binding of phosphoinositides by the PH do-
main reorients the DH and PH domains to engage effectively
Rho GTPases (Fig. 6). In the simplest scenario, binding of
phosphoinositides to the PH domain results in the en bloc
reorientation of the DH and PH domains relative to mem-
brane surfaces. However, a plethora of structural data (17,
20, 26, 34, 35) highlights a large degree of conformational
flexibility between PH domains and associated DH domains.
In the extreme case of Sos1, the PH domain must necessarily
move out of the way to allow access of Rho GTPases to the
major binding determinant within the DH domain subse-
quent to Rac activation dependent upon phosphoinositide
3-kinase (36). Therefore, perhaps it is more likely that bind-
ing of membrane-resident phosphoinositides to PH domains
serves to alter the relative orientation of DH and PH domains
to engage effectively Rho GTPases. These conformational
rearrangements could relieve inhibitory constraints in the
case of Sos1 and has been proposed for Vav (12) and Dbl (14,
37) or promote activation as has been suggested for Tiam1
(13, 38), Vav (12), and P-Rex1 (39). As previously discussed,
DbsCdc42 is organized to allow simultaneous engagement of
membranes by the PH domain of Dbs and the geranylgeranyl
group of Cdc42 (17). The structure of the complex further
suggests that membrane binding by the PH domain would
not preclude and, indeed, may favor concomitant interactions
between GTPases and the PH domain. Therefore, the PH
domain of Dbs, in concert with the DH domain, possibly
cooperates to integrate information regarding local fluctua-
tions in both Rho GTPase concentrations and the phospho-
inositide composition of nearby membranes.
In conclusion, we have used the recently determined struc-
ture of DbsCdc42 to design mutations within the PH domain of
Dbs that specifically impair either guanine nucleotide ex-
change or phospholipid binding in vitro and assessed their
functional effects in vivo. In agreement with both the structure
and in vitro biochemistry, the PH domain is an integral part of
the interface with GTPases required for efficient exchange in
vivo and mutations at sites within the PH domain that directly
perturb this interface severely impair cellular transformation
by Dbs. Similarly, cellular transformation and GTPase activa-
tion in vivo require the PH domain of Dbs to properly engage
phosphoinositides, but this requirement manifests only in the
presence of cellular membranes and membrane-associated
GTPases. Moreover, the PH domain clearly does not serve as a
simple membrane anchor or subcellular trafficking device de-
pendent upon binding phosphoinositides, because a variety of
forms of Dbs deficient in binding phosphoinositides to the PH
domain still localize correctly within cells. Although the details
await clarification, it seems likely that the invariant placement
of PH domains downstream of DH domains must serve an
invariant function. One intriguing possibility consistent with
these data is that the two domains function cooperatively to
detect specific membrane-resident GTPases and phospho-
inositides produced under controlled stimuli.
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